|
Hier für Unentschlossene, Perfektionisten und Tieftaucher, die History von Mannkind bis August 2013: March 10, 2008 – MannKind Corporation Response to Recent Market Events www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… September 16, 2008 – MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes Study 009 meets its primary endpoint of non-inferiority to a rapid-acting insulin analog www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… MKC-TI-009: www.clinicaltrials.gov/ct2/show/NCT00308308?term=Mannkind+00… MannKind and Pfizer Announce Collaboration for Certain Exubera Patients to Transition to MannKind's Inhaled Insulin Therapy www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… September 17, 2008 – MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… December 4, 2008 – MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… MKC-TI-030 www.clinicaltrials.gov/ct2/show/NCT00308737?term=Mannkind+03… MKC-TI-102 www.clinicaltrials.gov/ct2/show/NCT00309244?term=Mannkind+10… December 18, 2008 – MannKind Reports Top-Line Results from Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… January 13, 2009 – MannKind Reports Successful Completion of Device Bioequivalence Trial www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… February 26, 2009 – MannKind Updates Status of NDA Submission for AFRESA www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… March 9, 2009 – MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… March 16, 2009 – MannKind Submits NDA for AFRESA for Treatment of Diabetes www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… May 18, 2009 – FDA Accepts MannKind's Submission and Files NDA for AFRESA www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… June 6, 2009 – Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… June 8, 2009 – MannKind Unveils Next-Generation Inhalation System www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… June 22, 2009 – MannKind Closes Acquisition of Insulin Assets from Pfizer www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… July 14, 2009 – MannKind Announces Positive New Market Survey Information Regarding AFRESA(R) www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… September 29, 2009 – Study Shows AFRESA(R) Provides Rapid Suppression of Endogenous Glucose Production in Diabetes Patients www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… October 2, 2009 – AFRESA(R) Phase 3 Data Show Sustained Glycemic Control, Normal Lung Function in Patients over Four Years of Treatment www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… MKC-TI-010: www.clinicaltrials.gov/ct2/show/NCT00754624?term=mannkind+4+… October 29, 2009 – Studies Show Early Promise of MannKind's Cancer Immunotherapy Program in Melanoma, Prostate Cancer and Other Solid Malignancies www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… MKC1106-MT-001: www.clinicaltrials.gov/ct2/show/NCT00688090?term=mannkind+MK… MKC1106-PP-001: www.clinicaltrials.gov/ct2/show/NCT00423254?term=mannkind+MK… January 8, 2010 – MannKind Updates Status of New Drug Application www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… March 15, 2010 – FDA Requests Additional Information Regarding AFREZZA(TM) in Complete Response Letter to MannKind www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… June 10, 2010 – AFREZZA Demonstrates Non-Inferiority Compared to Standard Therapy in Controlling Blood Sugar Levels in Type 1 Diabetes Patients www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… MKC-TI-117: www.clinicaltrials.gov/ct2/show/NCT00700622?term=mannkind+16… July 20, 2010 – FDA Accepts AFREZZA Complete Response Resubmission and Sets Target Action Date www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… October 19, 2010 – MannKind Announces Initiation of Phase 2 Trial of Cancer Vaccine for Advanced Melanoma www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… MKC1106-MT-001: www.clinicaltrials.gov/ct2/show/NCT00688090?term=mannkind+MK… November 15, 2010 – New Findings Show Bioequivalence, Ease-of-Use and Efficiency of MannKind's Drug Delivery Platform www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… December 28, 2010 – MannKind Updates Status of New Drug Application for AFREZZA(R) www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… January 19, 2011 – MannKind Corporation Receives Complete Response Letter from the FDA for AFREZZA(R) www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… April 8, 2011 – MannKind Provides Regulatory Update www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… August 11, 2011 – MannKind Confirms Design of Pivotal Studies www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… May 31, 2012 – Pre-Clinical Data Demonstrates Promising Potential of MannKind’s IRE1α Inhibitor to Treat Multiple Myeloma www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… May 31, 2013 – MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… June 17, 2013 – MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… August 14 2013 – MannKind Announces Positive Clinical Data for AFREZZA; Both AFFINITY Phase 3 Studies Meet Primary Endpoints www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… CORRECTING and REPLACING MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-news… |
|
| aus der Diskussion: | Mannkind, Game-Chancer in Sachen Diabetik? |
| Autor (Datum des Eintrages): | sunny3999 (05.04.14 09:07:46) |
| Beitrag: | 341 von 6,825 (ID:46771335) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |